Abstract: Disclosed is an oral pharmaceutical formulation of pelubiprofen which is improved in dissolution rate and stability. As a result of an improvement in the dissolution rate of pelubiprofen, the oral pharmaceutical formulation can show high bioavailability and thus exert pharmacological effects thereof rapidly. It also can be stored with high stability as a result of the minimal generation of related compounds.

Abstract: Disclosed is a nuclease-resistant RNA aptamer for inhibiting the replication of HCV replicon. This aptamer is capable of binding specifically to HCV NS5B and inhibiting the proliferation of the HCV replicon, and includes at least one sequence selected from a group consisting of SEQ ID NOS. 1 to 4, in which a fluoro group is substituted for 2?-hydroxy of both U (uracil) and C (cytosine) bases, and SEQ ID NO. 17, in which the fluoro group is substituted for the 2?-hydroxy of both the U (uracil) and the C (cytosine) bases, and which is tagged with a cholesteryl group at a 5? end and with idT at a 3? end. The RNA aptamer is useful in the diagnosis and treatment of HCV infection.

Abstract: Disclosed is an oral pharmaceutical formulation of pelubiprofen which is improved in dissolution rate and stability. As a result of an improvement in the dissolution rate of pelubiprofen, the oral pharmaceutical formulation can show high bioavailability and thus exert pharmacological effects thereof rapidly. It also can be stored with high stability as a result of the minimal generation of related compounds.

Abstract: According to the present invention, an antianemic agent for the treatment of anemia caused by iron-deficiency containing iron and difructose. Iron and difructose contained in the said antianemic agent may form a complex, and their appropriate molar ratio is within the scope of 1:0.5 to 1:1000.Further, the antianemic agent in accordance with the present invention may additionally contain hematopoietics such as cyanocobalamine, pyridoxine hydrochloride, folic acid, etc.